SlideShare uma empresa Scribd logo
Dr.Gaafer Ibn Auf Specialized
    Children's Hospital

CASE PRESENTATION
Dr.Ibrahim Gamer eldawla Unit
         Pr esent ed by:

Dr. Yasser Mohammed Ahmed
   N e
     am              : H .A
                        .K .
   Age                  :     2½ yr s.
   Gender           :      Fem e.
                               al
   R dence
     esi           :    N H fa .
                         ew al
   Tr i be                : shukr i a.

   I nf or mant     :   her m her .
                              ot
   A i t t ed on : 31/m
      dm                ay/2009.
c/o
   Ski n r ash             1
    yr .

   Cough         1 week.
H.P.I
   Si nce 1yr m pt . suf f er i ng f r om
                     y
    ski n r ash      m nl y i n t he scal p,
                       ai
    f ace ant er i or chest , abdom   en and
    upper par t of t he back. i t ’s
    er yt hem us m
              at        acul o- papul ar , dr y.
    W hen      sl oughed       became      hypo
    pi gm ed ar eas & r ed cr ust s.
          ent
   A ssoci at ed w t h m l d i t chi ng& on
                   i     i
    and of f l ow gr ade f ever , pt . seen
    i n hal f a hosp. and gi ven t opi cal
    t r eat ment sever al t i mes f or hi s
    ski n l esi ons w t h out i m ovem .
                       i            pr     ent
   A so pt . adm t t ed t o H hospi t al
      l            i            .
    t hr ee t i mes dur i ng      l ast f ew
    m hs & ever y t i m pt . need
      ont                    e
    m t i pl e bl ood t r ansf usi ons and
      ul
    di schar ge w t h out
                    i               def i ni t e
    di agnosi s.
 7 days PTA pt . devel oped dr y
  cough , SO & m l d L.L sw l i ng .
                B   i         el
 Pt . di agnosed anaem c hear t f ai l ur e
                         i
  + chest i nf ect i on, gi ven bl ood &
  ant i bi ot i cs.
 t he m her not i ce t hat her chi l d
            ot
  not gai ni ng W and becam
                       t              e
  i r r i t abl e, her appet i t e poor , t her e
  w abd. di st ensi on w t h nor m
    as                           i         al
  bow habi t s.
        el
 Then pt . r ef er r ed t o G bn auf.i
  hospi t al f or m e i nvest i gat i ons.
                       or
Review of the systems:

 MSS: t her e i s m uscl e w i ng, no
                             ast
  j oi nt pai n or j oi nt sw l i ng.
                             el
 CNS: no l oss of consci ousness, no
  convul si ons, nor m hear i ng & vi si on
                       al
  no w  eakness.
 Renal S : ur i ne of nor m col our ,
                            al
  am ount & f r eq.
Past.M.H. :

   Past H of ear s di schar ge 3 m PTAo
    ext ended f or 1 m t r eat ed w t h ear
                       o             i
    dr yness & A .
                 B
   P     H   of     r epeat ed     hospi t al
    adm ssi ons & bl ood t r ansf usi ons.
        i
   no P H of bl eedi ng .
Developmental History:
 M pt out com of N
    y              e      SVD af t er
  uncom i cat ed pr egnancy.
          pl
 N per i or post nat al pr obl em
    o                                 s.
 She passed t hr ough nor m m l e
                              al i
  st ones t i l l age of 1 yr w  hen
  st ar t ed t o w k w t h out suppor t
                  al    i
  t hen st opped her e. now j ust
  st and, say f ew w d, but know a
                      or
  l ot .
 her devel opm alent     age b/w ( 1-
  1.5) yr .
Vaccination :
Vacci nat ed accor di ng t o ol d EPI w t h
                                       i
B G scar pr esent .
 C
Nutritional History :
Excl usi vel y br east f ed t i l l 4 mo.
W eaned at 1.5 yr s.
N ow on or di nar y f am l y di et
                          i
 , suf f i ci ent i n (C O pr ot ei ns
                        H,
 &f at s).
Family history:
31y                                38 yr s
H/W                              f ar mer




   17y          12y              8y      5y
  2.5y
no FH of si m l ar condi t i on.
              i
she has 4 si st er s, al l w e al i ve &
                            er
  w l.
   el
Social History :
 The l evel of educat i on of t he
  f at her & m her i s pr i m y school .
                ot              ar
 They l i ves i n t her e ow house w t h
                               n         i
  l i m t ed f aci l i t i es.
       i
 They ar e of l ow soci o-ecnom c i
  st at us.
 D sease has negat i ve r ef l ect i ons on
    i
  f am l y soci al l y & econom cal l y.
       i                         i
Drug History :
 O r egul ar use of t opi cal oi nt m s
    n                                 ent
  f or l ast one year .
 not know t o be al l er gi c t o any
            n
  dr ug t aken.
On Examination :
Pt l ooks i l l , pal e not j aundi ce not
  cyanosed
Vi t al si gns:
PR : 110 b/m ê nor m f eat ur es.
                           al
R : 35 c/m
 R
B 85/50 nor m
 P:               al
Tem 37.6 c˚
     p:
Anthropometric measures:
W :
   t       8 kg         bel ow t he 3r d
  cent i l e
 Lengt h : 73cm  bel ow t he 3r d
  cent i l e
 H : 45cm
   .C                 at t he 10t h
  cent i l e
 Head& neck:
 no dysm phi sm
           or       .(00)
 bot h f ont anel s w e cl osed.
                       er
 N ear s di schar ge w t h i nt act
    o                     i
  t ympani c m br ane.
               em
   Head& neck cont. :
    Lt sub m  andi bul er LN pal pabl e(3 4)cm
    (01) firm, not fixed or tender ê nor m cover i ng
                                          al
    ski n.
      R . pr eaur i cul ar & sub m
       t                            andi bul ar
  LN w e er
      si gni f i cant l y pal pabl e (2a, 2b).
 N ot her si gni f i cant l y pal pabl e
    o
  gr oup.
 Exam nat i on of t he or al cavi t y&
         i
  t hr oat w nor m .
                as        al
 Chest : sl i ght l y di st r essed, t r achea
  i s cent r al , no m ast i nal
                       edi
  shi f t , nor m ai r ent r y, nor m
                 al                    al
  vesi cul ar br eat hi ng w t h f ew
                              i
  scat t er ed cr eps bi l at er al l y no
  w heezes.
 CVS : apex at 5t h I C       S j ust out
  M L, t her e w gal l op r hyt hm &
    C               as
  shor t syst ol i c m m & LL oedem
                        ur ur               a
 ABDOMEN: di st ended, um l i cus f l at ,
                                 bi
      l i ver 6 cm B M sof t , t ender , sm h
                     C                     oot
  sur f ace, l i ver span 9 cm .
      spl een 4cm B M sm h sur f ace ,f i r m
                     C , oot
  .
        ki dneys not pal pabl e, no asci t es.
      no pal pabl e Par a A LN her neal
                                 ,
  or i f i ces w e, nor m ext . geni t al i a ,
                er       al
  PR not done.
 CNS: nor m   al
 MMS: no j oi nt sw l i ng or
                        el
  t ender ness.
   SKIN:
    m acul o papul ar br ow t o r ed r ash
                             n
    cover ed al l f ace & scal p (03), t he
    ant er i or chest , abdomen (4a, 4b)
    and upper par t of t he back.
       upper &l ow l i m w e f r ee,
                   er      b er
       som r ashes heal ed t o hypo
            e
    pi gm ed
         ent        spot s (05).
SKIN cont. :
 hai r spar se but of nor m col our .
                              al
  t her e i s pet echi al r ash i n t he
 sol e s of f eet (06).
Summary
   2½ yr s f em e w t h hi st or y of m
                  al   i                    acul o
    papul ar er yt hm ous ski n r ash f or one
                     at
    yr , al so she had hi st or y of ot i t i s
    m a & f r equent B . acut el y
      edi                   T
    pr esent ed w t h s/s of anaem c H
                  i                   i    F.
        O/E pal e, di f f use ski n r ash. A sol
    t her e hepat o- spl enom egal y& cer vi cal
    L. adenopat hy
        LL edem ++.
                a
Differential diagnosis
 Langer hans cel l hi st i ocyt osi s(LC ).
                                         H
A LL.
 Lym phom a.
 Li pi d st or age di seases:
   –G usher 's di sease t ype1.
   – N em
      i ann Pi ck di sease t ype B    .
Investigations:
BFFM : - ve
  U i ne anal ysi s: cl ear .
   r
  St ool anal ysi s: cl ear .
  ur i ne f or m abol i c scr eeni ng :
                et                         -
ve
  RG
   B:       6.1 m ol /l .
                 m
  scr eeni ng f or H V: -ve
                     I
  scr eeni ng f or hepat i t i s B C : -ve
                                  &
  m oux t est : -ve
   ant
CBC
date     2/6/09       9/6/09        15/6/09        N.V
HB       2 g/dl       3.4 g/dl      3.6 g/dl      (11-17)g/dl

RBC      660 10³/µl   1260 10³/µl   1410 10³/µl   (3900-5300) 10³/µl
HCT      7%           13%           11.3%         (35-45)%
MCV      100 fl                     83 fl         (80- 96) fl
MCH      30 pg                      25.5 pg       (28- 32) pg

MCHC     29 g/dl                    30.5 g/dl     (32- 36) g/dl
TWBC     7.1 10³/µl   3.2 10³/µl    13.7 10³/µl   (4.0-11.0) 10³/µl

N        67 %                       30 %          (50-80)%
L        30 %                       64 %          (25-50)%
M        3%                         6%            (2-7)%

Retics   6.9%                                     (0.2-2)%

PLT      64 10³/µl    30 10³/µl     34 10³/µl     (150-400) 10³/µl
ESR      100
   P.B ct ur e:
       .Pi
    Ver y sever e anaem a w t h pol y
                       i   i
    chr om a.
           asi
    PLT l ow  .
    W C nor m .
      B         al

    H el ect r ophor esi s:
     B                        A/A

     PT : 13 sec
    (11- 15)
     PTT: 26 sec
    (26- 36)
RFT & Electrolytes:
Date                     2/6/09         N.V

urea                     11 mmol/l      (4- 8) mmol/l

creatinine                70.4 µmol/l   (70-133) µmol/l

S.Sodium                 130 mmol/l     (132-142) mmol/l

S.Potasium                3.2 mmol/l    (3.2- 5.2) mmol/l

S.Calcium (total)         2 mmol/l      (2.1- 2.5) mmol/l

S.Phosphorus             0.96 mmol/l     (1.2-2.2) mmol/l

S.Uric acid              202 µmol/l       (100-350) µmol/l
LFT& Enzymes
Date        3/6/09      N.V

TSB         32 µmol/l   <34 µmol/l

Direct      11 µmol/l   <3.4 µmol/l


T.Protein   62 g/l      (61- 75) g/l

S.Albumin   26 g/l      (32- 50) g/l

AST         35 u/l      (15- 55) u/l

ALT         35 u/l      (5- 45) u/l

ALP         85 u/l      (145-420) u/l
U/S abdomen 6/6
      l i ver enl ar ged w t h nor m t ext ur e,
                            i        al
  por t al vei n not di l at ed &nor m  al GB
  &bi l i ar y syst em .
 Spl een: show m    oder at e homogenous
  enl ar gem .ent
 B h ki dneys : nor m , no cal cul i or
    ot                     al
  r el at ed m  asses.
 U :w l s sm h and r egul ar , no
    .B al          oot
  cal cul i .
 N abdom nal or pel vi c m
    o         i                   asses or cyst s.
 N f r ee f l ui ds col l ect i on.
    o
   C : (show
      XR           )
       Skul l X R     ay: ( 1, 2 , 3)
       L L l ong bones x R : (show
                                 ay         )
R ol ogy r epor t :
 adi
C : r i bs & bot h hum s i nvol vem
 XR                        our           ent
   (l yt i c l esi ons), nor m l ungs+ m
                              al           od.
   car di om  egal y.
 Skul l : m t i pl e l yt i c(punched out )
            ul
   l esi ons, al so know as (geogr aphi cal
                           n
   skul l ).
LL: Lt f em & R . t i bi a i nvol vem .
              ur     t                 ent
Pel vi s& V. C um show no i nvol vem .
                 ol n:                      ent
Bone marrow aspirate& biopsy:14/6
 A r at i on: dr y t ap
  spi
 PB di m phi c bl ood pi ct ur e w t h t ar get
    P:      or                          i
  cel l & nucl eat ed R C seen.
                          B
 W C adequat e w t h m ocyt e not ed.
  B                 i     yel
 PLT r educed. (Leuko-er yt hobl ast i c
  pi ct ur e ).
(Show B sl i des 01, 02, 03).
           .M
      adequat e Tr ephi ne bi opsy t aken w t h   i
  f r agm ed bony t r abecul ae ext r em y
         ent                                    el
  hyper cel l uar w t h depr essed
                      i
  haem  opoi esi s, m r ow i s i nf i l t r at e by
                       ar
Bone marrow aspirate& biopsy:14/6
f i ndi ng consi st ent w t h LC .
                         i      H
  f or speci al st ai n w t h C 1a, S100.
                         i      D

st ai ni ng w t h S100 w
             i          as    +ve
 (t el ephone com ent done i n m l i t ar y
                  m             i
 hosp.)
DIAGNOSIS :

LCH class IIIa.
Management :
 Counsel i ng.
 Suppor t i ve t r eat m .
                         ent
     B ood t r ansf usi on
       l
       t opi cal oi nt ment
C hem her apy.
         ot
       st er oi d& vi nbl ast i n
 Fol l ow up.
Fol l ow up pl an:
1. C i ni cal l y. 0a, 0b, 0c
       l
2. Lab :
  – C Cdone 8/8/009 , LFT , bl eedi ng
        B
      pr of i l e .
  – B   one m r ow 1a , 1b). done13/8/009
                ar  .(
  (conc: LC i n hem ol ogi cal
               H       at
      r em ssi on).
          i
3. R adi ol ogi cal :
  – C & Skel et al sur vey.
        XR
4. EN consul t at i on.
       T
Literature review :
 Histiocytic Disorders
 cl ass1 ( LC )   H
     N m hi st i ocyt es or i gi nat e f r om
       or al
  pl eur i pot ent st em cel l s .
    Under t he ef f ect of var i ous cyt oki nes ,
  hi st i ocyt es di f f er ent i at e t o speci al i zed
  cel l s :m  onocyt es ,t i ssue m ophages
                                     acr
  dendr i t i c cel l s and l anger hans cel l s.
  t hese cel l s becam ant i gen pr esent i ng
                         e
  cel l s and som have phagocyt i c
                     e
  act i vi t i es.
 H st i ocyt osi s ar e het er ogeneous gr oup
    i
  of uncom on pr ol i f er at i ve di seases
             m
  i nvol vi ng B der i ved i m at ur e
                  .M               m
  hi st i ocyt i c cel l s , w ch can have m e
                              hi               or
  r eact i ve t han m i gnant f eat ur es.
                       al
 W O cl assi f i cat i on of hi st i ocyt i c
    H
  di sor der s:
 C ass I
    l          dendr i t i c cel l r el at ed
  di sor der s. (LC ) :
                    H
I           Si ngl e bone
II          M t i pl e bone
               ul
 I I I A bone + sof t t i ssues
    C ass I I (m ophage r el at ed di sor der )
       l            acr
     :
1.   H st i ocyt osi s of m
       i                      ononucl ear
     phagocyt es ot her t han LC     s
2.   1r y& 2r y hem   ophagocyt i c
     l ym phohi st i ocyt osi s.
3.   Si nus hi st i ocyt osi s w t h m
                                  i    assi ve
     l ym phadenopat hy (R   osai -D f m
                                     or an)
4.   Juveni l e xant hogr anul om (JXG
                                    a     )
5.   R i cul o hi st i ocyt om
       et                        a
 C ass I I I M i gnant hi st i ocyt i c
   l              al
  di sor der s :
1. A cut e monocyt i c l eukem a (FA M
                                i    B 5).
2. M i gnant hi st i ocyt osi s.
     al
3. Tr ue hi st i ocyt i c l ymphom .
                                  a
   C i dence l evel s f or t he di agnosi s of
     onf
    LC :H
     – pr esum i ve : l i ght m phol ogi c
                pt               or
       char act er i st i cs .
     – Designated : above + ≥2 posi t i ve st ai ns
       of :
      1. A denosi ne t r i phosphat ase
      2. S-100 pr ot ei n.

      3. A pha –D m
           l        - annosi dase .
      4. Peanut l ect i n.

     – D i ni t i ve : l i ght + B r beck gr anul es
         ef                       i
       and/ or C 1aD
Poor pr ognost i c f eat ur es :
1. I nvol vem ent of t he r i sk or gans w t hi
   dysf unct i on (l ungs ,br ai n , l i ver , B ).
                                                M
2. Lack of r api d r esponse t o chem her apy
                                           ot
   .
3. A bsence of bone di sease
 The w st pr ognosi s i s associ at ed w t h
          or                                    i
   cl ass I I I b (Let t er er Si w i t h a
                                   e),w
   5year s sur vi val of 50% w t h i nt ensi ve
                                    i
   chem her apy.
        ot
    A under 2 yr s at di agnosi s w t hout
      ge                                    i
  “R SK
     I ”                          or gan
THANKS

Mais conteúdo relacionado

Semelhante a My Case(case presentation LCH, in SMSB

Introduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To Sheershasana Dr Shriniwas KashalikarIntroduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To Sheershasana Dr Shriniwas Kashalikaryashodhank
 
Introduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To  Sheershasana  Dr  Shriniwas  KashalikarIntroduction To  Sheershasana  Dr  Shriniwas  Kashalikar
Introduction To Sheershasana Dr Shriniwas Kashalikarnamitam
 
Introduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To  Sheershasana  Dr  Shriniwas  KashalikarIntroduction To  Sheershasana  Dr  Shriniwas  Kashalikar
Introduction To Sheershasana Dr Shriniwas Kashalikarkrupeshcha
 
Applied Physiology Healing Physiology Dr Shriniwas Kashalikar
Applied Physiology Healing Physiology  Dr  Shriniwas KashalikarApplied Physiology Healing Physiology  Dr  Shriniwas Kashalikar
Applied Physiology Healing Physiology Dr Shriniwas Kashalikardrsprasadi
 
Bronchiectases
BronchiectasesBronchiectases
BronchiectasesRohan Jose
 
RESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docx
RESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docxRESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docx
RESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docxverad6
 
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...
S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...sanjaykhanke
 
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...
S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...ghanyog
 
Stress and major diseases presentation
Stress and major diseases presentationStress and major diseases presentation
Stress and major diseases presentationjoha1777
 
IND-ENG-55921-2013
IND-ENG-55921-2013IND-ENG-55921-2013
IND-ENG-55921-2013icandfc
 
The french new wave
The french new waveThe french new wave
The french new wavemjsmith_uk
 
The french new wave.doc
The french new wave.docThe french new wave.doc
The french new wave.docmjsmith_uk
 
Anti slavery rebellions - nat turner
Anti slavery rebellions - nat turnerAnti slavery rebellions - nat turner
Anti slavery rebellions - nat turnerRhiana Prendergast
 
5 1 6 T o w a r d A l t e r n a t i v e s i n H e a l t h .docx
5 1 6  T o w a r d  A l t e r n a t i v e s  i n  H e a l t h .docx5 1 6  T o w a r d  A l t e r n a t i v e s  i n  H e a l t h .docx
5 1 6 T o w a r d A l t e r n a t i v e s i n H e a l t h .docxalinainglis
 
Fitzgerald report 1953
Fitzgerald report 1953Fitzgerald report 1953
Fitzgerald report 1953Norman Gates
 
Vieroots Products Training Personalise Solution
Vieroots Products Training Personalise SolutionVieroots Products Training Personalise Solution
Vieroots Products Training Personalise SolutionDeepak Mohanty
 

Semelhante a My Case(case presentation LCH, in SMSB (20)

Introduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To Sheershasana Dr Shriniwas KashalikarIntroduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To Sheershasana Dr Shriniwas Kashalikar
 
Introduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To  Sheershasana  Dr  Shriniwas  KashalikarIntroduction To  Sheershasana  Dr  Shriniwas  Kashalikar
Introduction To Sheershasana Dr Shriniwas Kashalikar
 
Introduction To Sheershasana Dr Shriniwas Kashalikar
Introduction To  Sheershasana  Dr  Shriniwas  KashalikarIntroduction To  Sheershasana  Dr  Shriniwas  Kashalikar
Introduction To Sheershasana Dr Shriniwas Kashalikar
 
Diabetes
DiabetesDiabetes
Diabetes
 
Aboriton
AboritonAboriton
Aboriton
 
Applied Physiology Healing Physiology Dr Shriniwas Kashalikar
Applied Physiology Healing Physiology  Dr  Shriniwas KashalikarApplied Physiology Healing Physiology  Dr  Shriniwas Kashalikar
Applied Physiology Healing Physiology Dr Shriniwas Kashalikar
 
Be stylishsalon
Be stylishsalonBe stylishsalon
Be stylishsalon
 
Bronchiectases
BronchiectasesBronchiectases
Bronchiectases
 
RESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docx
RESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docxRESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docx
RESEARCH FROM McMASTER UNIVERSITY SHOWS THAT CANADIANS TEND TO.docx
 
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...
S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...
 
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...
S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...S T U D Y  O F  H U M A N  P H Y S I O L O G Y  D R  S H R I N I W A S  K A S...
S T U D Y O F H U M A N P H Y S I O L O G Y D R S H R I N I W A S K A S...
 
Stress and major diseases presentation
Stress and major diseases presentationStress and major diseases presentation
Stress and major diseases presentation
 
IND-ENG-55921-2013
IND-ENG-55921-2013IND-ENG-55921-2013
IND-ENG-55921-2013
 
The french new wave
The french new waveThe french new wave
The french new wave
 
The french new wave.doc
The french new wave.docThe french new wave.doc
The french new wave.doc
 
Anti slavery rebellions - nat turner
Anti slavery rebellions - nat turnerAnti slavery rebellions - nat turner
Anti slavery rebellions - nat turner
 
5 1 6 T o w a r d A l t e r n a t i v e s i n H e a l t h .docx
5 1 6  T o w a r d  A l t e r n a t i v e s  i n  H e a l t h .docx5 1 6  T o w a r d  A l t e r n a t i v e s  i n  H e a l t h .docx
5 1 6 T o w a r d A l t e r n a t i v e s i n H e a l t h .docx
 
Mar 2017 issue 1 Integrity Health Coaching Centers in NH
Mar 2017  issue 1  Integrity Health Coaching Centers in NHMar 2017  issue 1  Integrity Health Coaching Centers in NH
Mar 2017 issue 1 Integrity Health Coaching Centers in NH
 
Fitzgerald report 1953
Fitzgerald report 1953Fitzgerald report 1953
Fitzgerald report 1953
 
Vieroots Products Training Personalise Solution
Vieroots Products Training Personalise SolutionVieroots Products Training Personalise Solution
Vieroots Products Training Personalise Solution
 

Último

Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryDr Simran Deepak Vangani
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgeryKafrELShiekh University
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptdesktoppc
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartMedicoseAcademics
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationMedicoseAcademics
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Catherine Liao
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Catherine Liao
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerSherrylee83
 
CNN-based plastic waste detection system
CNN-based plastic waste detection systemCNN-based plastic waste detection system
CNN-based plastic waste detection systemBOHRInternationalJou1
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghanahealthwatchghana
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMeenakshiGursamy
 
MRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxMRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxDr. Dheeraj Kumar
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediatesdorademei
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxSamar Tharwat
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesTina Purnat
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cancer Institute NSW
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxgauripg8
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxdrwaque
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionGolden Helix
 

Último (20)

Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
CNN-based plastic waste detection system
CNN-based plastic waste detection systemCNN-based plastic waste detection system
CNN-based plastic waste detection system
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
MRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxMRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptx
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 

My Case(case presentation LCH, in SMSB

  • 1. Dr.Gaafer Ibn Auf Specialized Children's Hospital CASE PRESENTATION Dr.Ibrahim Gamer eldawla Unit Pr esent ed by: Dr. Yasser Mohammed Ahmed
  • 2. N e am : H .A .K .  Age : 2½ yr s.  Gender : Fem e. al  R dence esi : N H fa . ew al  Tr i be : shukr i a.  I nf or mant : her m her . ot  A i t t ed on : 31/m dm ay/2009.
  • 3. c/o  Ski n r ash 1 yr .  Cough 1 week.
  • 4. H.P.I  Si nce 1yr m pt . suf f er i ng f r om y ski n r ash m nl y i n t he scal p, ai f ace ant er i or chest , abdom en and upper par t of t he back. i t ’s er yt hem us m at acul o- papul ar , dr y. W hen sl oughed became hypo pi gm ed ar eas & r ed cr ust s. ent
  • 5. A ssoci at ed w t h m l d i t chi ng& on i i and of f l ow gr ade f ever , pt . seen i n hal f a hosp. and gi ven t opi cal t r eat ment sever al t i mes f or hi s ski n l esi ons w t h out i m ovem . i pr ent
  • 6. A so pt . adm t t ed t o H hospi t al l i . t hr ee t i mes dur i ng l ast f ew m hs & ever y t i m pt . need ont e m t i pl e bl ood t r ansf usi ons and ul di schar ge w t h out i def i ni t e di agnosi s.
  • 7.  7 days PTA pt . devel oped dr y cough , SO & m l d L.L sw l i ng . B i el  Pt . di agnosed anaem c hear t f ai l ur e i + chest i nf ect i on, gi ven bl ood & ant i bi ot i cs.
  • 8.  t he m her not i ce t hat her chi l d ot not gai ni ng W and becam t e i r r i t abl e, her appet i t e poor , t her e w abd. di st ensi on w t h nor m as i al bow habi t s. el  Then pt . r ef er r ed t o G bn auf.i hospi t al f or m e i nvest i gat i ons. or
  • 9. Review of the systems:  MSS: t her e i s m uscl e w i ng, no ast j oi nt pai n or j oi nt sw l i ng. el  CNS: no l oss of consci ousness, no convul si ons, nor m hear i ng & vi si on al no w eakness.  Renal S : ur i ne of nor m col our , al am ount & f r eq.
  • 10. Past.M.H. :  Past H of ear s di schar ge 3 m PTAo ext ended f or 1 m t r eat ed w t h ear o i dr yness & A . B  P H of r epeat ed hospi t al adm ssi ons & bl ood t r ansf usi ons. i  no P H of bl eedi ng .
  • 11. Developmental History:  M pt out com of N y e SVD af t er uncom i cat ed pr egnancy. pl  N per i or post nat al pr obl em o s.  She passed t hr ough nor m m l e al i st ones t i l l age of 1 yr w hen st ar t ed t o w k w t h out suppor t al i t hen st opped her e. now j ust st and, say f ew w d, but know a or l ot .  her devel opm alent age b/w ( 1- 1.5) yr .
  • 12. Vaccination : Vacci nat ed accor di ng t o ol d EPI w t h i B G scar pr esent . C
  • 13. Nutritional History : Excl usi vel y br east f ed t i l l 4 mo. W eaned at 1.5 yr s. N ow on or di nar y f am l y di et i , suf f i ci ent i n (C O pr ot ei ns H, &f at s).
  • 14. Family history: 31y 38 yr s H/W f ar mer 17y 12y 8y 5y 2.5y no FH of si m l ar condi t i on. i she has 4 si st er s, al l w e al i ve & er w l. el
  • 15. Social History :  The l evel of educat i on of t he f at her & m her i s pr i m y school . ot ar  They l i ves i n t her e ow house w t h n i l i m t ed f aci l i t i es. i  They ar e of l ow soci o-ecnom c i st at us.  D sease has negat i ve r ef l ect i ons on i f am l y soci al l y & econom cal l y. i i
  • 16. Drug History :  O r egul ar use of t opi cal oi nt m s n ent f or l ast one year .  not know t o be al l er gi c t o any n dr ug t aken.
  • 17. On Examination : Pt l ooks i l l , pal e not j aundi ce not cyanosed Vi t al si gns: PR : 110 b/m ê nor m f eat ur es. al R : 35 c/m R B 85/50 nor m P: al Tem 37.6 c˚ p:
  • 18. Anthropometric measures: W : t 8 kg bel ow t he 3r d cent i l e  Lengt h : 73cm bel ow t he 3r d cent i l e  H : 45cm .C at t he 10t h cent i l e
  • 19.  Head& neck:  no dysm phi sm or .(00)  bot h f ont anel s w e cl osed. er  N ear s di schar ge w t h i nt act o i t ympani c m br ane. em
  • 20. Head& neck cont. : Lt sub m andi bul er LN pal pabl e(3 4)cm (01) firm, not fixed or tender ê nor m cover i ng al ski n. R . pr eaur i cul ar & sub m t andi bul ar LN w e er si gni f i cant l y pal pabl e (2a, 2b).  N ot her si gni f i cant l y pal pabl e o gr oup.  Exam nat i on of t he or al cavi t y& i t hr oat w nor m . as al
  • 21.  Chest : sl i ght l y di st r essed, t r achea i s cent r al , no m ast i nal edi shi f t , nor m ai r ent r y, nor m al al vesi cul ar br eat hi ng w t h f ew i scat t er ed cr eps bi l at er al l y no w heezes.  CVS : apex at 5t h I C S j ust out M L, t her e w gal l op r hyt hm & C as shor t syst ol i c m m & LL oedem ur ur a
  • 22.  ABDOMEN: di st ended, um l i cus f l at , bi l i ver 6 cm B M sof t , t ender , sm h C oot sur f ace, l i ver span 9 cm . spl een 4cm B M sm h sur f ace ,f i r m C , oot . ki dneys not pal pabl e, no asci t es. no pal pabl e Par a A LN her neal , or i f i ces w e, nor m ext . geni t al i a , er al PR not done.  CNS: nor m al  MMS: no j oi nt sw l i ng or el t ender ness.
  • 23. SKIN: m acul o papul ar br ow t o r ed r ash n cover ed al l f ace & scal p (03), t he ant er i or chest , abdomen (4a, 4b) and upper par t of t he back. upper &l ow l i m w e f r ee, er b er som r ashes heal ed t o hypo e pi gm ed ent spot s (05).
  • 24. SKIN cont. : hai r spar se but of nor m col our . al t her e i s pet echi al r ash i n t he sol e s of f eet (06).
  • 25. Summary  2½ yr s f em e w t h hi st or y of m al i acul o papul ar er yt hm ous ski n r ash f or one at yr , al so she had hi st or y of ot i t i s m a & f r equent B . acut el y edi T pr esent ed w t h s/s of anaem c H i i F. O/E pal e, di f f use ski n r ash. A sol t her e hepat o- spl enom egal y& cer vi cal L. adenopat hy LL edem ++. a
  • 26. Differential diagnosis  Langer hans cel l hi st i ocyt osi s(LC ). H A LL.  Lym phom a.  Li pi d st or age di seases: –G usher 's di sease t ype1. – N em i ann Pi ck di sease t ype B .
  • 27. Investigations: BFFM : - ve U i ne anal ysi s: cl ear . r St ool anal ysi s: cl ear . ur i ne f or m abol i c scr eeni ng : et - ve RG B: 6.1 m ol /l . m scr eeni ng f or H V: -ve I scr eeni ng f or hepat i t i s B C : -ve & m oux t est : -ve ant
  • 28. CBC date 2/6/09 9/6/09 15/6/09 N.V HB 2 g/dl 3.4 g/dl 3.6 g/dl (11-17)g/dl RBC 660 10³/µl 1260 10³/µl 1410 10³/µl (3900-5300) 10³/µl HCT 7% 13% 11.3% (35-45)% MCV 100 fl 83 fl (80- 96) fl MCH 30 pg 25.5 pg (28- 32) pg MCHC 29 g/dl 30.5 g/dl (32- 36) g/dl TWBC 7.1 10³/µl 3.2 10³/µl 13.7 10³/µl (4.0-11.0) 10³/µl N 67 % 30 % (50-80)% L 30 % 64 % (25-50)% M 3% 6% (2-7)% Retics 6.9% (0.2-2)% PLT 64 10³/µl 30 10³/µl 34 10³/µl (150-400) 10³/µl ESR 100
  • 29. P.B ct ur e: .Pi Ver y sever e anaem a w t h pol y i i chr om a. asi PLT l ow . W C nor m . B al H el ect r ophor esi s: B A/A PT : 13 sec (11- 15) PTT: 26 sec (26- 36)
  • 30. RFT & Electrolytes: Date 2/6/09 N.V urea 11 mmol/l (4- 8) mmol/l creatinine 70.4 µmol/l (70-133) µmol/l S.Sodium 130 mmol/l (132-142) mmol/l S.Potasium 3.2 mmol/l (3.2- 5.2) mmol/l S.Calcium (total) 2 mmol/l (2.1- 2.5) mmol/l S.Phosphorus 0.96 mmol/l (1.2-2.2) mmol/l S.Uric acid 202 µmol/l (100-350) µmol/l
  • 31. LFT& Enzymes Date 3/6/09 N.V TSB 32 µmol/l <34 µmol/l Direct 11 µmol/l <3.4 µmol/l T.Protein 62 g/l (61- 75) g/l S.Albumin 26 g/l (32- 50) g/l AST 35 u/l (15- 55) u/l ALT 35 u/l (5- 45) u/l ALP 85 u/l (145-420) u/l
  • 32. U/S abdomen 6/6  l i ver enl ar ged w t h nor m t ext ur e, i al por t al vei n not di l at ed &nor m al GB &bi l i ar y syst em .  Spl een: show m oder at e homogenous enl ar gem .ent  B h ki dneys : nor m , no cal cul i or ot al r el at ed m asses.  U :w l s sm h and r egul ar , no .B al oot cal cul i .  N abdom nal or pel vi c m o i asses or cyst s.  N f r ee f l ui ds col l ect i on. o
  • 33. C : (show XR )  Skul l X R ay: ( 1, 2 , 3)  L L l ong bones x R : (show ay ) R ol ogy r epor t : adi C : r i bs & bot h hum s i nvol vem XR our ent (l yt i c l esi ons), nor m l ungs+ m al od. car di om egal y. Skul l : m t i pl e l yt i c(punched out ) ul l esi ons, al so know as (geogr aphi cal n skul l ). LL: Lt f em & R . t i bi a i nvol vem . ur t ent Pel vi s& V. C um show no i nvol vem . ol n: ent
  • 34. Bone marrow aspirate& biopsy:14/6 A r at i on: dr y t ap spi PB di m phi c bl ood pi ct ur e w t h t ar get P: or i cel l & nucl eat ed R C seen. B W C adequat e w t h m ocyt e not ed. B i yel PLT r educed. (Leuko-er yt hobl ast i c pi ct ur e ). (Show B sl i des 01, 02, 03). .M adequat e Tr ephi ne bi opsy t aken w t h i f r agm ed bony t r abecul ae ext r em y ent el hyper cel l uar w t h depr essed i haem opoi esi s, m r ow i s i nf i l t r at e by ar
  • 35. Bone marrow aspirate& biopsy:14/6 f i ndi ng consi st ent w t h LC . i H f or speci al st ai n w t h C 1a, S100. i D st ai ni ng w t h S100 w i as +ve (t el ephone com ent done i n m l i t ar y m i hosp.)
  • 37. Management :  Counsel i ng.  Suppor t i ve t r eat m . ent B ood t r ansf usi on l t opi cal oi nt ment C hem her apy. ot st er oi d& vi nbl ast i n  Fol l ow up.
  • 38. Fol l ow up pl an: 1. C i ni cal l y. 0a, 0b, 0c l 2. Lab : – C Cdone 8/8/009 , LFT , bl eedi ng B pr of i l e . – B one m r ow 1a , 1b). done13/8/009 ar .( (conc: LC i n hem ol ogi cal H at r em ssi on). i 3. R adi ol ogi cal : – C & Skel et al sur vey. XR 4. EN consul t at i on. T
  • 39. Literature review :  Histiocytic Disorders  cl ass1 ( LC ) H N m hi st i ocyt es or i gi nat e f r om or al pl eur i pot ent st em cel l s . Under t he ef f ect of var i ous cyt oki nes , hi st i ocyt es di f f er ent i at e t o speci al i zed cel l s :m onocyt es ,t i ssue m ophages acr dendr i t i c cel l s and l anger hans cel l s. t hese cel l s becam ant i gen pr esent i ng e cel l s and som have phagocyt i c e act i vi t i es.
  • 40.  H st i ocyt osi s ar e het er ogeneous gr oup i of uncom on pr ol i f er at i ve di seases m i nvol vi ng B der i ved i m at ur e .M m hi st i ocyt i c cel l s , w ch can have m e hi or r eact i ve t han m i gnant f eat ur es. al  W O cl assi f i cat i on of hi st i ocyt i c H di sor der s:  C ass I l dendr i t i c cel l r el at ed di sor der s. (LC ) : H I Si ngl e bone II M t i pl e bone ul  I I I A bone + sof t t i ssues
  • 41. C ass I I (m ophage r el at ed di sor der ) l acr : 1. H st i ocyt osi s of m i ononucl ear phagocyt es ot her t han LC s 2. 1r y& 2r y hem ophagocyt i c l ym phohi st i ocyt osi s. 3. Si nus hi st i ocyt osi s w t h m i assi ve l ym phadenopat hy (R osai -D f m or an) 4. Juveni l e xant hogr anul om (JXG a ) 5. R i cul o hi st i ocyt om et a
  • 42.  C ass I I I M i gnant hi st i ocyt i c l al di sor der s : 1. A cut e monocyt i c l eukem a (FA M i B 5). 2. M i gnant hi st i ocyt osi s. al 3. Tr ue hi st i ocyt i c l ymphom . a
  • 43. C i dence l evel s f or t he di agnosi s of onf LC :H – pr esum i ve : l i ght m phol ogi c pt or char act er i st i cs . – Designated : above + ≥2 posi t i ve st ai ns of : 1. A denosi ne t r i phosphat ase 2. S-100 pr ot ei n. 3. A pha –D m l - annosi dase . 4. Peanut l ect i n. – D i ni t i ve : l i ght + B r beck gr anul es ef i and/ or C 1aD
  • 44. Poor pr ognost i c f eat ur es : 1. I nvol vem ent of t he r i sk or gans w t hi dysf unct i on (l ungs ,br ai n , l i ver , B ). M 2. Lack of r api d r esponse t o chem her apy ot . 3. A bsence of bone di sease  The w st pr ognosi s i s associ at ed w t h or i cl ass I I I b (Let t er er Si w i t h a e),w 5year s sur vi val of 50% w t h i nt ensi ve i chem her apy. ot  A under 2 yr s at di agnosi s w t hout ge i “R SK I ” or gan